Comparison
BPC-157 vs TB-500
A structural comparison of BPC-157 and TB-500 (thymosin beta-4 fragment) by classification, sequence length, molecular profile and supplied format.
BPC-157 vs TB-500
This page compares the compounds as materials: what class each belongs to, what the molecule looks like, and how each is supplied. It is a structural and analytical reference — it makes no efficacy claims and contains no protocols.
Side-by-side profile
| Property | BPC-157 | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Classification | synthetic pentadecapeptide derived from gastric juice protein BPC | synthetic fragment of thymosin beta-4 |
| Other designations | Body Protection Compound 157 | — |
| Molecular weight | 1419.5 g/mol | 4963 g/mol |
| Reported half-life | short (minutes in plasma) | ~2–3 days |
| Supplied vial sizes | 5 mg / 10 mg | 10 mg |
| Purity specification | ≥99% HPLC | ≥99% HPLC |
| Research focus | tissue-repair and gastrointestinal models | actin-binding and repair-model research |
Reading the comparison
Receptor classification is the meaningful difference between these compounds; vial size and purity specification are supply characteristics, not properties of the molecule. Where molecular weights differ substantially, expect different reconstitution arithmetic for the same nominal vial mass — run each through the peptide calculator.
Individual references
- BPC-157
- TB-500 (Thymosin Beta-4)
Documentation supplied by PX1 Research
Every PX1 lot ships with HPLC purity, LC-MS identity confirmation, residual solvent, moisture (Karl Fischer), sterility and endotoxin data. Lot records are published at /coa and /endotoxin-reports. Synthesis, purification, lyophilization and vial fill are performed in U.S. facilities — see /manufacturing-process.
Research use only. PX1 Research supplies compounds for laboratory and in-vitro research. Nothing on this page is medical advice, a dosing recommendation, or an offer for human or veterinary use.